#USA #H.I.G. Capital #Miami #investment success #Celerion

H.I.G. Capital Successfully Completes Celerion Sale

H.I.G. Capital, a prominent player in the global alternative investment landscape, has finalized the sale of Celerion Holdings, Inc. for an impressive $1.8 billion. This marks a significant milestone in H.I.G.’s ongoing successes, reinforcing their commitment to strategic investments in high-quality businesses.

Forging Ahead in Value Creation

Celerion, recognized within the clinical pharmacology field, operates as a leading Contract Research Organization (CRO). This strategic move follows a series of successful sales within H.I.G.'s Advantage strategy which has also seen the completion of transactions involving St. Croix and United Flow Technologies, amassing a total enterprise value exceeding $4.5 billion since late 2025.

H.I.G. Capital's Advantage strategy is distinct in its focus on identifying and nurturing top-tier North American companies, thus demonstrating an impressive ability to recognize valuable businesses and implement strategies that deliver remarkable outcomes for their investors.

Insights from H.I.G. Leadership

Co-Heads of H.I.G. Advantage, Matt Hankins and Rahul Vinnakota, emphasized the strategic nature of the Celerion transaction, stating, "This sale is indicative of our capability to pinpoint exceptional businesses in specialized sectors, supported by our extensive operational and strategic resources. The closing represents a significant achievement for our investors and validates our unique approach to value creation. We take pride in what we have accomplished with Celerion and are transitioning it into its promising next phase."

Celerion's Role in Clinical Research

Celerion has carved a niche for itself in the realm of clinical research, providing crucial trial solutions for pharmaceutical and biotechnology firms. With its expansive network of facilities, it delivers comprehensive services ranging from first-in-human trials to bioanalytical laboratory services, managing data and biometrics effectively throughout the drug development process.

Through this latest undertaking, H.I.G. Capital showcases not just its prowess in identifying lucrative ventures but also its commitment to building scalable businesses across various sectors and regions. Their strategy not only returns value to investors but also strengthens the companies within their portfolio, preparing them for sustained growth in the future.

About H.I.G. Capital

With a robust capital portfolio of $75 billion under management, H.I.G. Capital stands as a leader in alternative investments. The firm is headquartered in Miami and maintains a wide-reaching presence throughout the United States with additional offices across major cities in Europe, Latin America, and Asia. Their investment strategies include providing both equity and debt as well as engaging in management buyouts aimed at enhancing the operational effectiveness of each venture.

Since its inception in 1993, H.I.G. Capital has successfully invested in over 400 businesses globally, with its current portfolio encompassing more than 100 companies generating collective revenues in excess of $53 billion. For further insights into their investments and management strategies, the firm’s official website offers comprehensive resources.